Stuttgart - Delayed Quote EUR

2GH.SG,0P0001LG60,0 (2GH.SG)

51.00

0.00

(0.00%)

At close: July 23 at 10:00:00 PM GMT+2

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonic

GlobeNewswire 9 days ago

MRUS
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET. The webcast of th

GlobeNewswire last month

MRUS
Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)

One thing we could say about the analysts on Merus N.V. ( NASDAQ:MRUS ) - they aren't optimistic, having just made a...

Simply Wall St. 2 months ago

MRUS
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 - Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical dat

GlobeNewswire 2 months ago

MRUS
Merus to Present at Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET Leerin

GlobeNewswire 2 months ago

MRUS
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to petosemtamab in combination with pembrolizuma

GlobeNewswire 2 months ago

MRUS
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi's 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET. The webcast of the presentation will be contemporaneously available on

GlobeNewswire 2 months ago

MRUS
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma

GlobeNewswire 2 months ago

MRUS
Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

MRUS
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus’ leading Biclonics® technology platform, and Biohaven’s next-generation ADC conjugation and payload platform technologies. Under the terms of the agreement, Biohaven is responsible for the pr

GlobeNewswire 3 months ago

MRUS

BHVN
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company’s phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics® targeting EGFR and LGR5. The phase 2, open

GlobeNewswire 4 months ago

MRUS
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025 – Conference Call on Saturday, December 7th at 9:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-len

GlobeNewswire 4 months ago

MRUS
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1Merus and Partner Therapeutics announced a license agreement for U.S. commercialization UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific

GlobeNewswire 4 months ago

MRUS
Merus price target lowered to $109 from $111 at Guggenheim

Guggenheim lowered the firm’s price target on Merus (MRUS) to $109 from $111 and keeps a Buy rating on the shares after the company announced an exclusive agreement with privately-held Partner Therapeutics to exclusively licensed to PTx the right to commercialize zenocutuzumab for the treatment of NRG1 fusion-positive cancer in the U.S. The firm is updating its model to account for the license agreement, the analyst tells investors. Published first on TheFly – the ultimate source for real-time,

TipRanks 4 months ago

MRUS
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) and Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company with a focus in hematology and oncology, today announced they have entered into an agreement in which Merus has exclusively licensed to PTx the righ

GlobeNewswire 4 months ago

MRUS
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication

GlobeNewswire 4 months ago

MRUS
Merus Receives FDA extension of PDUFA for zenocutuzumab

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for zenocutuzumab (Zeno) Biologics License Application (BLA) currently under priority review. T

GlobeNewswire 5 months ago

MRUS
Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Merus ( NASDAQ:MRUS ) Third Quarter 2024 Results Key Financial Results Revenue: US$11.8m (up 6.7% from 3Q 2023). Net...

Simply Wall St. 5 months ago

MRUS
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical data accepted for rapid oral presentation at ESMO® Asia Congress 2024 Based on the Company’s current operating plan, existing cash, cash equivalents, and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) --

GlobeNewswire 5 months ago

MRUS
Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Simply Wall St. 6 months ago

MRUS

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

2GH.SG,0P0001LG60,0 (2GH.SG)

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Merus to Present at Upcoming Investor Conferences

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus price target lowered to $109 from $111 at Guggenheim

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Receives FDA extension of PDUFA for zenocutuzumab

Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain